REACH Participant Diversity Program

项目摘要 加州大学旧金山分校以患者为中心的慢性下腰痛(REACH)机制表型核心中心是一家 U-19背痛联盟(BACPAC)机制研究中心(MRC)，由Help to End资助 上瘾是长期(治愈)的主动性。作为MRC，REACH专注于慢性下腰痛的发现 (CLBP)机制，为深度表型分析生成数据，并开发允许靶向 针对个别患者的治疗。REACH由杰弗里·洛兹博士领导，大卫·S·布拉德福德医学博士被捐赠 加州大学旧金山分校整形外科主席、科内研究副主席，康纳·奥尼尔， 医学博士，该部门的非手术脊柱计划主任。其他REACH调查人员包括 加州大学戴维斯分校、欧文分校和圣地亚哥分校的合作者。 加州大学旧金山分校以患者为中心的慢性下腰痛(REACH)机制表型核心中心是一个U- 19背痛联盟(BACPAC)机制研究中心(MRC)，由Hear资助。作为一名MRC， REACH专注于cLBP机制和表型的发现，这最终将导致精确度 治疗慢性腰背痛的药物。 REACH正在进行两项纵向队列研究，回归和回家。在这两项研究中，数据元素 从心理、生物和社会领域进行了测量。Backhome是一项无站点的数字研究， 不需要面对面的访问。所有数据都是从患者调查中收集的(即轻度表型分析)。在……里面 卷土重来，轻表型通过大量需要面对面的深度表型措施得到加强 就诊(例如，核磁共振、身体机能测试、定量感觉测试、抽血)。每项研究的持续时间 是两年。复出的目标招生人数为400人，家乡的目标招生人数为5000人。招生 加州大学旧金山分校的其他三个地点(戴维斯，欧文， 和圣地亚哥)。 除了复出和回国，REACH还将参加bacpac协作临床 研究(CCS)，计划于2月开始从美国各地的多个网站招募受试者 2022年CCS将利用顺序、多分配随机试验(SMART)设计来确定 与cLBP治疗反应相关的表型。 CLBP研究参与者必须反映美国人口的多样性，这一点至关重要。然而，到目前为止， 在背痛研究的注册人数中，少数族裔的代表一直不足。我们建议的目标是 优化REACH cLBP研究中的多样性和包容性。

Project Summary The UCSF Core Center for Patient-centric Mechanistic Phenotyping in Chronic Low Back Pain (REACH) is a U-19 Back Pain Consortium (BACPAC) Mechanistic Research Center (MRC), funded by the Helping to End Addiction Long-term (HEAL) initiative. As an MRC, REACH is focused on discovery of chronic low back pain (cLBP) mechanisms, generating data for deep phenotyping, and developing algorithms that allow targeting of therapies to individual patients. REACH is led by Jeffrey Lotz, PhD, the David S. Bradford M.D. Endowed Chair in Orthopaedic Surgery at UCSF, and Vice Chair of Research within the Department, and Conor O'Neill, MD, Director of the Department's Non-Operative Spine Program. Other REACH investigators include collaborators at UC Davis, UC Irvine, and UC San Diego. The UCSF Core Center for Patient-centric Mechanistic Phenotyping in Chronic Low Back Pain (REACH) is a U- 19 Back Pain Consortium (BACPAC) Mechanistic Research Center (MRC), funded by HEAL. As an MRC, REACH is focused on discovery of cLBP mechanisms and phenotypes, which will ultimately lead to precision medicine for cLBP. REACH is conducting two longitudinal cohort studies, comeBack and BackHome. In both studies, data elements from psychological, biological, and social domains are measured. BackHome is a site-less, digital study that does not require an in-person visit. All data is collected from patient surveys (i.e., light phenotyping). In comeBack, light phenotyping is augmented by a number of deep phenotyping measures that require an in-person visit (e.g., MRI, physical function testing, quantitative sensory testing, blood draw). The duration of each study is two years. The target enrollment for comeBack is 400 subjects, and for BackHome 5000 subjects. Enrollment from UCSF will be supplemented by collaborators at three other University of California locations (Davis, Irvine, and San Diego). In addition to comeBACK and BackHome, REACH will be participating in the BACPAC Collaborative Clinical Study (CCS), which is scheduled to start enrolling subjects from a number of sites across the US in February of 2022. The CCS will utilize a sequential, multiple assignment randomized trial (SMART) design to identify phenotypes associated with response to cLBP treatments. It is vital that cLBP study participants reflect the diversity of the United States population. To date, however, minorities have been under-represented in back pain study enrollment. The objective of our proposal is to optimize diversity and inclusion in REACH cLBP studies.